Secukinumab for heart and kidney health in people with metabolic syndrome
Treatments studied
Part of Brain & nervous system, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether secukinumab, an injectable drug that reduces inflammation, can improve heart and kidney health in people who have both heart disease and kidney disease along with metabolic issues like diabetes or obesity. If you qualify, you may receive the drug or a placebo, and your health will be closely monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have at least one metabolic problem, such as being overweight, having a larger waistline, borderline or high blood sugar, high triglycerides, or a history of high blood pressure, metabolic syndrome, or diabetes.
- You have chronic kidney disease (reduced kidney function or protein in your urine).
- You have a history of atherosclerotic cardiovascular disease, such as a previous heart attack, stroke, or blocked arteries in your heart, neck, or legs.
- You are not currently on immune-suppressing medications, have not had a recent heart event, and have no active infections or other major health conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether clazakizumab can reduce the risk of heart attacks or strokes in people with high levels of inflammation (measured by a blood test called hsCRP) and conditions like heart disease, obesity, diabetes, high blood pressure, or kidney disease. If you qualify, you'll receive either the study drug or a placebo to see if it helps lower your risk.
This study tests a new approach to protect the heart and kidneys in people with both chronic kidney disease and heart or blood vessel problems. By optimising treatment, researchers hope to reduce the risk of further kidney or heart damage.
This study looks at whether secukinumab (a drug used for hidradenitis suppurativa) affects heart health in people who also have high heart risk or heart plaque. You'd receive the standard care with secukinumab and undergo special heart imaging to see how the drug affects your arteries.
This trial tests a drug called secukinumab to see if it can help people with severe Takayasu arteritis, a rare disease that causes inflammation in the blood vessels. The drug works by blocking a protein that drives inflammation, which may reduce disease activity and help people lower their steroid dose.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
Hear when a new Atherosclerotic Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.